. All of the issued US. Patents discussed above refer to caffeine as a "stimulator of metabolism" or in one case a "lipolytic agent".
Apublished placebo-controlled double blind human clini cal study has demonstrated that caffeine ingestion increased the levels of free fatty acids (the products of lipolysis) in young men in a statistically signi?cant manner. The increase in free fatty acids after caffeine challenge Was not related to alterations in norepinephrine kinetics or fat oxidation (Arciero et al. 1995) .
Several physiological sites are regulated to a signi?cant degree by A1 adenosine receptors. These are the brain (Williams and Bumstock 1997) , the heart (Kollias-Baker et al. 1995) , adipose tissue (van der Graaf et al. 1999 ) and the coordination of glucose and lipid metabolism (van Schaick et al. 1998) . Attempts to affect the function of speci?c organs or tissues by the use of adenosine or synthetic adenosine analogues acting as agonists or antagonists Would seemingly produce global effects leading to intolerable side effects. This is not the case hoWever, because of the blood brain barrier, Which protects the brain from hydrophilic agents and the much greater sensitivity of adipocytes-metabolic A1 adenosine receptors toWards adenosine and its agonists in comparison to the heart A1 adenosine receptors. The overall sensitivity of adipose tissue anti-lipolytic A1 adenosine receptors toWards adenosine, considering both the tissue density of the receptors and the sensitivity of the receptors'intracellular coupling, Was reported to be 38 times higher than the sensitivity of A1 adenosine receptors regu lating cardiac functions (van der Graaf et al. 1999) . Adipose tissue-metabolic A1 adenosine receptors are therefore a good therapeutic target, taking into account their sensitivity toWards adenosine in comparison to other potential thera peutic targets, Which is expected to yield signi?cant ef?cacy With a manageable spectrum of side effects. One condition is that the agonist for the adipose tissue-metabolic A1 adenosine receptors has to be a relatively loW affinity agonist, since a high af?nity agonist is expected to interact With loW affinity A1 adenosine receptors on other organs and produce signi?cant side effects (van der Graaf et al. 1999 ).
Adenosine itself is knoWn to be such an agonist (Jacobson and van Rhee 1997) . The reason that it has not been used for these therapeutic targets is its extremely short blood plasma half-life, limiting any efficacy and potential usefulness (Williams and Burnstock 1997) . The present invention dis closes and teaches a method for consistently and chronically elevating blood plasma adenosine levels for achieving adi pose tissue-metabolic therapeutic targets Without any side effects.
The short blood plasma half-life of adenosine of 3-6 seconds (Williams and Burnstock 1997) made it an ideal compound for the treatment of supraventricular tachycardia, a form of cardiac arrhythmia, for Which use it has been approved in man as a bolus injection (Kollias-Baker et al. 1995) . The therapeutic use of adenosine in the form of a bolus injection has been successful strictly because of the acute nature of the adenosine administration, preventing What is de?ned as receptor desensitiZation (Linden 1997) . Chronic administration of synthetic A1 adenosine receptor agonists Was reported to produce marked desensitiZation of the heart's adenosine A1 receptors (Shryock et al. 1989; Lee et al. 1993) DesensitiZation of receptors is a general phenomenon, Whereby chronic exposure of sensitive receptors to their agonists can produce a marked reduction in the capacity of the receptors to respond to the same or related agonists. The same phenomena have also been termed refractoriness, tolerance or tachyphylaxis (Hoppe and Lohse 1995) . The A1 adenosine receptors, both in cardiac and adipose tissues have been demonstrated to undergo desensitiZation after chronic exposure to adenosine analogues that are proven agonists for the A1 adenosine receptors. DesensitiZation of the A1 adenosine receptors in both tissues Was demonstrated to be mediated by both a reduction in receptor density (numbers) and a decrease in the sensitivity of the receptor's coupling to the intracellular Gi proteins (Hoppe and Lohse 1995) . The Gi proteins act in transducing the receptors' signal inside the target cell. The A1 adenosine receptors desensitiZation is used as a therapeutic target as disclosed and taught by the present invention. By reducing the overall sensitivity of the adipose tissue-metabolic A1 adenosine receptors as a result of chronic administration of adenosine, the effectiveness of adenosine as an endogenous anti lipolytic agent is signi?cantly diminished. As importantly, antagonism of adenosine at these sites, by common A1 adenosine receptor antagonists such as caffeine or theophylline, is markedly enhanced. DesensitiZation of adi pose tissue-metabolic A1 adenosine receptors does not affect heart or brain A1 adenosine receptors because of the heart's receptors much loWer sensitivity (van der Graaf 1999) and the brain's effective barrier against systemic adenosine (Williams and Burnstock 1997) .
SUMMARY OF THE INVENTION
The present invention discloses and teaches: The preparation of a stable pharmaceutical and therapeutic composition of adenosine 5'-triphosphate (ATP) or physi ologically acceptable salt thereof suitable for oral deliv ery. The invention provides for a stable oral dosage form such as a pill of ATP or physiologically acceptable salt thereof along With ?llers, binders, stabiliZers and enteric coating materials. The objective of the oral delivery of ATP is to achieve systemic absorption of adenosine. A method for the chronic administration of adenosine using an ATP oral dosage form (eg pill) as a pro-drug for the chronic elevation of extracellular adenosine. Extracellular adenosine interacts With a variety of adenosine receptors regulating functions of organs and tissues. Amethod for the chronic administration of adenosine for the purpose of desensitiZing adipose tissue-metabolic A1 adenosine receptors. The utility of this method is in decreasing the sensitivities of these receptors toWards adenosine and at the same time increasing the sensitivities of these receptors toWards adenosine antagonists such as caffeine or theophilline. This method is used for the purpose of inducing Weight loss in humans or in the treatment of obesity in humans. Since the adipose tissue metabolic A1 adenosine receptors act in inhibiting lipoly sis (degradation of fats), reductions in their activities as a result of chronic exposure to adenosine is suffecient to induce lipolysis and effective Weight loss. Chronic expo sure to adenosine, can be supplemented by caffeine or theophilline, both commonly used drugs in order to fur ther reduce the activities of adipose tissue-metabolic A1 adenosine receptors, thus achieving a more enhanced Weight loss. The term "chronic administration" and simi lar terms used herein refer to prolonged or substantially sustained release over an extended period of time, typi cally at least about 96 hours. polymer that dissolves at a speci?c pH. In the case of ATP, the catabolic enZymes that catalyZe the degradation of purines are present in the stomach and the proximal small intestines (Mohamedali et al. 1993) . Thus a pH-sensitive enteric coating can be designed to release ATP as the therapeutically active agent in the distal part of the small intestine, the ileum, Where catabolic activities that catalyZe the degradation of ATP are minimal (Mohamedi et al. 1993 ).
The human stomach has a variable acidic pH of about 1 to 2 and the transit time of a pill through the stomach is betWeen 20 minutes and 2 hours, depending on the prandial state. An ATP pill passing through the stomach intact Would enter the small intestine, Which consists of the duodenum, jejunum and ileum. Transit time of a pill throughout the small intestine is relatively steady at approximately 3 hours. FolloWing the small intestine, an enteric stable pill then passes through the large intestine, Which consists of the caceum, the ascending colon, the transverse colon, the descending colon and the sigmoid colon. Total transit time through the large intestine is about 30-35 hours. Even though the distal part of the small intestine, the ileum, has someWhat greater catabolic activities on ATP than the colon, three of its properties make areas of the ileum very suitable sites for the release of ATP from enteric pills. First, a pH spectrum that enables the design of a pH-sensitive enteric coated pill, releasing the ATP at the desired site. The pH of the small intestine gradually rises from about 5-5.5 in the duodenal bulb, the site of gastric emptying, to about 7.2 in the distal parts of the ileum. The pH then drops at the ileum-caceum junction to about 6.3 and gradually increases to about 7 in the descending (left) colon. Second, absorption of purines from the small intestine is fast, providing for minimal degradation after release of the therapeutically active substance and a predictable delivery of speci?c dos age forms. Third, residence times to the point of release in the distal part of the small intestine are predictable (3-4.5 hours). The function of the pH-dependent enteric coating is to prevent release of the therapeutically active pro-drug-AT P, Eudragit S is a poly(metacrylic acid, methylmetacrylate) 1:2 and Eudragit L is a poly(metacrylic acid, methylmetacrylate) 1:1. Both are anionic copolymers Where the ratios refer to the ratios of free carboxyl groups to methyl ester groups. Both copolymers have a mean molecular Weight of 135,000.
These tWo copolymers can be mixed in a variety of ratios to achieve a mechanically stable coating of pH sensitivity of betWeen pH's 6 and 7, With Eudragit S being the preferred ingredient.
After the release of the therapeutic composition of ATP in the small intestine, absorption of adenosine and inorganic phosphate-the catabolic products of ATP, or of ATP itself then folloWs. Absorption of ATP itself is folloWed by a rapid degradation to adenosine and inorganic phosphate inside the vascular bed (Slakey et al. 1990; Rapaport and Fontaine 1989b) . Both the adenosine and inorganic phosphate are then incorporated into the liver ATP pools (steady state levels), effectively expanding-these pools (Rapaport and Zamecnik 1976; . The turnover of the expanded liver ATP pools, ATP pools Which supply the adenosine precursor for red blood cell ATP synthesis, then lead to the expansion of red blood cell ATP pools. Expanded red blood cell ATP pools are in turn released from red blood cells into the blood plasma compartment (extracellular) via a non-hemolytic mechanism, Where they are rapidly degraded to adenosine and inorganic phosphate (Slakey et al. 1990; Rapaport 1990 ). The overall established mechanism thus provides for the sloW, continuous release of adenosine in the blood plasma after the release of ATP at a preferred position along the distal part of the small intestine. 
EXAMPLE 2
Each of the AT P-formulation tablets Was coated With four different types of coating. The primary considerations in selecting these coating materials Were that they should be of sufficient mechanical strength, provide good protection in acidic media and release the therapeutic composition of ATP at pH 6.8 or higher. The folloWing enteric formulations Were used: 1. Eudragit FS30D, Which is an acqueous version of Eudragit S, coated to 8% coating.
2. Eudragit S 100, coated from acetone/methanol to a 6% coating.
3. Eudragit S 100, coated from acetone/methanol to a 8% coating. All of the above coatings release ATP at a pH of
4. A mixture of Eudragit L100 (dissolves at pH 5.5) and Eudragit S100 (at a 20:80 ratio) coated from acetone/ methanol to a 8% coating. Enteric coating number 4
released ATP at a pH of 6.7-6.8. TWo overWeight human volunteers ingested 1000 mg per day of enteric coated ATP pills of enteric coating type 4 of Example 2. The subjects Were not coffee drinkers or con sumers of any other form of caffeine. After three Weeks, one subject lost 4 pounds and the other subject lost 6 pounds Without altering any other behavioral parameter such as diet or exercise.
EXAMPLE 4
TWo overWeight human volunteers Who are coffee drinkers, consuming an average of tWo cups of coffee per day, or 110-150 milligrams of caffeine, ingested 1000 mg per day of enteric coated ATP pills of enteric coating type 4 of Example 2. After three Weeks one subject lost 5 pounds and the other subject lost 6 pounds Without altering any other behavioral parameter such as diet or exercise.
The data discussed above lead to the folloWing conclu sions:
Asafe, stable, ingestable therapeutic composition of adenos ine 5'-triphosphate disodium (ATP) in a form of a tablet containing more than 100 milligrams of ATP can be prepared using binders, ?llers and stabiliZers Well-knoWn to the skilled artisan.
A safe, stable ingestable therapeutic composition of ATP in a form of an enteric coated pill designed to dissolve in the distal part of the small intestine, can be prepared contain ing more than 100 milligrams of ATP per pill. The distal portion of the small intestine, the ileum, contains the loWest levels of catabolic enZymes catalyZing the degra dation of ATP and adenosine. A method for the chronic continuous administration of adenosine, Which is the major catabolic product of its Purinergic Approaches in Experimental Therapeutics, Jacobson K. A. and Jarvis M. F. Editors, Wiley-Liss, 1997, pp 3-26 
